This simple blood test might detect depression before symptoms appear

NYU researchers say a blood-based epigenetic marker could help identify depressive symptoms that are harder to spot in a clinic, especially symptoms that are not tied to physical complaints.

The study was published online ahead of print in March and highlighted again in NYU’s May 4 press release. It examined 440 women in the Women’s Interagency HIV Study, including women with and without HIV.

What the study found

The researchers reported that a monocyte epigenetic age measure, called MonoDNAmAge or EAAMono, was associated with the non-somatic depressive symptom domain and with anhedonia in particular. Non-somatic symptoms include things like loss of interest, hopelessness and other cognitive or mood-related features that can be harder to detect than bodily symptoms.

The association held in the HIV subgroup as well. By contrast, a broader Horvath epigenetic age measure was not associated with depression severity or symptom domains.

Why it matters

The result suggests a potential biomarker for depression rather than a finished diagnostic tool. If the finding holds up in larger and more diverse studies, it could eventually support earlier detection of people whose symptoms are easy to miss in routine care.

That said, the research does not mean doctors can order a validated blood test for depression today. The study is best understood as an early step toward that possibility.

What happens next

The big questions are whether the marker replicates in broader populations and whether it can be turned into a practical clinical test. For now, the research is promising but preliminary.